LONDON (Alliance News) - Faron Pharmaceuticals Ltd said Wednesday that new data from its cell surface receptor Clever-1 showed B cell response control and humoral antibody production.
The company said the new data comes from work by Dunkel and colleagues, published online by Frontiers in Immunology.
"The data suggest that Clever-1 serves as an endogenous immunosuppressive molecule in monocytes macrophages, where it maintains the production of inflammatory cytokines at physiological levels," the company explained.
Deleting or neutralizing Clever-1, has previously been reported to augment antitumour immune responses in melanoma, lymphoma and breast cancer, Faron said.
Chief Executive Officer Markku Jalkanen said: "This is a fascinating finding and builds up further evidence for the importance to control Clever-1 function in conditions where active immune suppression can cause disease or worsen disease development."
Faron shares were trading up 8.1% at 119.50 pence each.
Faron Pharmaceuticals (FARN)